These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 36613878)

  • 1. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
    Khanam A; Kottilil S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.
    Chen C; Wang Z; Ding Y; Qin Y
    Front Immunol; 2023; 14():1133308. PubMed ID: 36845131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
    Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.
    Sas Z; Cendrowicz E; Weinhäuser I; Rygiel TP
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
    Zhao M; Huang H; He F; Fu X
    Front Immunol; 2023; 14():1188277. PubMed ID: 37275909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatocellular carcinoma immune microenvironment].
    Miao TG; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):923-930. PubMed ID: 36299184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling.
    Yang J; He J; Feng Y; Xiang M
    Front Immunol; 2023; 14():1166440. PubMed ID: 37266440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.
    Pan X; Ni S; Hu K
    Biomaterials; 2024 Apr; 306():122481. PubMed ID: 38286109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging immunotherapy for HCC: A guide for hepatologists.
    Foerster F; Gairing SJ; Ilyas SI; Galle PR
    Hepatology; 2022 Jun; 75(6):1604-1626. PubMed ID: 35253934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.
    Sung PS
    Clin Mol Hepatol; 2022 Jul; 28(3):333-350. PubMed ID: 34665953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
    Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
    Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Compounds Originating from the Nature to Act in Hepatocellular Carcinoma Therapy by Targeting the Tumor Immunosuppressive Microenvironment: A Review.
    Li Y; Li H; He Q; Yang X
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.
    Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R
    Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.
    Nishida N; Kudo M
    Oncology; 2017; 92 Suppl 1():40-49. PubMed ID: 27764823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma.
    Lim CJ; Chew V
    Semin Liver Dis; 2020 May; 40(2):131-142. PubMed ID: 31810095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
    Chen J; Gingold JA; Su X
    Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.